Table 3. MCL incidence rates for non-Hispanic white, male and patients with advanced stage tumor, SEER and Texas areas, 1995–2013.
| SEER | ||||||
|---|---|---|---|---|---|---|
| non-Hispanic White | Male | Advanced stage tumor | ||||
| Incidencea 95% CI | Count | Incidencea 95% CI | Count | Incidencea 95% CI | Count | |
| Year of diagnosis | ||||||
| 1995–1999 | 0.88 (0.82–0.94) | 849 | 1.20 (1.11–1.3) | 622 | 0.55 (0.51–0.59) | 653 |
| 2000–2003 | 1.05 (0.98–1.12) | 856 | 1.52 (1.4–1.64) | 679 | 0.70 (0.65–0.76) | 721 |
| 2004–2008 | 1.25 (1.19–1.32) | 1,363 | 1.71 (1.6–1.81) | 1,044 | 0.83 (0.78–0.88) | 1,157 |
| 2009–2013 | 1.31 (1.24–1.37) | 1,549 | 1.78 (1.68–1.89) | 1,225 | 0.89 (0.84–0.94) | 1,388 |
| 1995–2013 | 1.13 (1.1–1.17) | 4,617 | 1.58 (1.52–1.63) | 3,570 | 0.76 (0.73–0.78) | 3,919 |
| PC 1995–2013 | 99.72 | 109.82 | 156.66 | |||
| APC 1995–2013 | 2.83* | 2.71* | 3.33* | |||
| Age at diagnosis | ||||||
| 20–49 | 0.14 (0.12–0.16) | 262 | 0.16 (0.14–0.18) | 261 | 0.09 (0.08–0.1) | 289 |
| 50–59 | 1.25 (1.16–1.35) | 729 | 1.53 (1.42–1.65) | 675 | 0.84 (0.78–0.91) | 762 |
| 60–69 | 2.87 (2.7–3.05) | 1,088 | 3.76 (3.53–4.01) | 1,001 | 1.94 (1.83–2.06) | 1,098 |
| 70–79 | 4.69 (4.43–4.96) | 1,244 | 6.24 (5.86–6.63) | 1,015 | 2.93 (2.76–3.11) | 1,100 |
| 80+ | 4.72 (4.41–5.04) | 859 | 7.22 (6.66–7.81) | 618 | 2.80 (2.59–3.02) | 670 |